# ADAPT-C (NCT04585490)

> Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04585490
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Stanford University
- Conditions: Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc
- Interventions: Durvalumab; Carboplatin; Pemetrexed; Paclitaxel; Cisplatin; AVENIO ctDNA Surveillance Kit; Tremelimumab
- Enrollment: 48
- Primary outcome: Change in ctDNA Level Following Chemotherapy

## Indexed commentary on ADAPT-C so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=adapt-c-nct04585490